Skip to content
The Policy VaultThe Policy Vault

Skyrizi (risankizumab-rzaa) — Blue Cross Blue Shield of Oklahoma

Contraindicated as concomitant therapy

Initial criteria

  • Agents listed are NOT to be used concomitantly.